AlphAIAlphAI — Financial news for AI agents
SEC EDGAROCT 51 min read$CORT

Vieira Roberto Wandenkolk sold $967K of CORT

Vieira Roberto Wandenkolk (President, Oncology) sold 8,333 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $116.10 ($114.52–$116.58, $0.97M total) across 3 trades on 2026-10-02 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Vieira Roberto Wandenkolk
Published Oct 5, 2026, 11:58 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 12:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CORT
Bearish
medium confidence
Mentioned
$CORT
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTBearishLow
01

Why it matters

The disclosed sale reduces insider ownership and may be interpreted as a mild bearish indicator, though the amount is modest.

02

Market read

A routine insider sell of under $1M, modestly reducing insider stake; limited trading relevance.

03

What to watch

No new product or trial data disclosed; the transaction is isolated.

Relevance 4/10Novelty 4/10Timing: post‑market today

Background

SEC Form 4 filing discloses insider transactions; investors monitor these for potential signals.

Company-level read

Ticker impact

$CORTBearishMedium confidence
Context

President of Oncology sold 8,333 shares for $967K via a 10b5‑1 plan, reducing his stake to 3,946 shares.

Expected impact

likely pressure as investors price in the insider sell

Evidence & confidence

The sale is a routine 10b5‑1 transaction of under $1M; market may view it as a slight bearish cue.

Market effects

Sector

Minimal impact on biotech sector; typical insider transaction.

Regional

None

Global

None

Counterpoint

What could challenge this read

The sale could be purely procedural; no change in fundamentals.

Key entities

  • Company
    Corcept Therapeutics Inc

    Biopharma focused on cortisol‑related therapies, ticker CORT.

  • Executive
    Vieira Roberto Wandenkolk

    President, Oncology at Corcept Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CORT insider trading history →

Related articles

OCT 26
$CORTHighAI 8/10

Why is Corcept Therapeutics stock rallying today?

Corcept Therapeutics (CORT) stock rose 3.7% in pre-market trading after reporting positive Phase 2 BELLA trial results for Lifyorli in combination with nab-paclitaxel and bevacizumab in platinum-resistant ovarian cancer. The study showed improved median progression-free survival (7.2 months) and objective response rate (59%) compared to the two-drug combination. The stock had previously declined 29.6% due to competitive concerns from Genmab's trial results.

investing.com2 min
OCT 23
$CORTHighAI 8/10

Corcept Therapeutics (CORT) Shares Drop 20% on Genmab's Phase 3

Corcept Therapeutics (CORT) shares dropped 20% to $85.86 after Genmab's phase 3 trial for a competing ovarian cancer drug succeeded, raising concerns about market competition. CORT's GF Value™ suggests it is 11.2% overvalued, while its GF Score™ is 85/100, indicating strong financial health. Insiders have sold $101.5M in shares over the past year, signaling caution.

gurufocus.com3 min
OCT 23
$CORTHighAI 8/10

Why is Corcept Therapeutics stock tumbling today?

Corcept Therapeutics (CORT) shares fell 12.9% after Genmab's rival drug showed positive results in a Phase 3 trial for platinum-resistant ovarian cancer, directly competing with Corcept's Lifyorli. The decline was exacerbated by prior downgrades and market headwinds, with shares dropping from $106.05 to a low of $90.99 before partially recovering to $93.68.

investing.com2 min
SEP 22
$CORTHighAI 8/10

Corcept’s (CORT) Cancer Drug Just Cleared Europe’s Toughest Hurdle

Corcept Therapeutics (CORT) announced that Europe's drug regulator recommended approval for its cancer therapy, relacorilant, for use with chemotherapy in platinum-resistant ovarian cancer. The recommendation is based on a Phase 3 trial showing improved patient outcomes. The European Commission's final decision is expected in Q4 2026. Corcept reported $47.6M in Q2 revenue from Lifyorli (relacorilant) and raised its full-year revenue guidance to $1.1B-$1.2B, with net income increasing to $43M.

insidermonkey.com3 min